Sun Pharma has agreed to buy Organon in an all-cash $11.75 billion deal, including debt. The takeover expands its reach in women's health and marks a sharper global push.

Sun Pharma announces $11.75 billion acquisition of Organon, enhancing its global footprint in women’s health and biosimilars.

Sun Pharma announces $11.75 billion acquisition of Organon, enhancing its global footprint in women’s health and biosimilars.

Sun Pharma just made the biggest bet in Indian pharma history. Markets loved it instantly. Here’s why investors backed the Organon deal despite the massive price tag.

Sun Pharma will acquire Organon in an all-cash deal valued at about $11.75 billion including debt. The move expands its women’s health footprint, adds global scale and helped lift the stock about 5%.